| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2007 | CA2627670A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors |
| 05/10/2007 | CA2627598A1 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 05/10/2007 | CA2627585A1 Rnai inhibition of influenza virus replication |
| 05/10/2007 | CA2627584A1 Multi-layered coating technology for taste masking |
| 05/10/2007 | CA2627547A1 Methods of treating atrial fibrillation with p38 inhibitor compounds |
| 05/10/2007 | CA2627546A1 3 -monosubstituted tropane derivatives as nociceptin receptor ligands |
| 05/10/2007 | CA2627516A1 Triazole compounds as lipoxygenase inhibitors |
| 05/10/2007 | CA2627423A1 Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors |
| 05/10/2007 | CA2627307A1 Pharmaceutical use of substituted amides |
| 05/10/2007 | CA2627306A1 Pharmaceutical use of substituted amides |
| 05/10/2007 | CA2627242A1 Compositions and methods for treating inflammatory disorders |
| 05/10/2007 | CA2627177A1 Piperidine glycine transporter inhibitors |
| 05/10/2007 | CA2626586A1 Stable composition for a pharmaceutical formulation containing olanzapine |
| 05/10/2007 | CA2626585A1 A pharmaceutical formulation containing olanzapine |
| 05/10/2007 | CA2626504A1 Tricyclo substituted amides as glucokinase modulators |
| 05/10/2007 | CA2626475A1 Tricyclo substituted amides |
| 05/10/2007 | CA2626435A1 Hypophosphorous acid derivatives and their therapeutical applications |
| 05/10/2007 | CA2626350A1 Compounds and compositions as protein kinase inhibitors |
| 05/10/2007 | CA2626074A1 A combination of cannabinoids for the treatment of peripheral neurophatic pain |
| 05/10/2007 | CA2625835A1 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| 05/10/2007 | CA2625210A1 Gaba receptor mediated modulation of neurogenesis |
| 05/10/2007 | CA2625096A1 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | CA2624625A1 Tetrahydronaphthyridine derivative |
| 05/10/2007 | CA2621985A1 Sigma ligands for neuronal regeneration and functional recovery |
| 05/10/2007 | CA2618799A1 Aqueous anaesthetic compositions comprising propofol |
| 05/10/2007 | CA2616915A1 Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
| 05/10/2007 | CA2611031A1 Unsolvated benzodiazepine compositions and methods |
| 05/10/2007 | CA2610480A1 Nanoparticulate acetaminophen formulations |
| 05/10/2007 | CA2610265A1 Methods for producing micrornas |
| 05/10/2007 | CA2609985A1 Modulation of cell barrier dysfunction |
| 05/09/2007 | EP1783645A1 Methods for the identification of microRNA and their applications in research and human health |
| 05/09/2007 | EP1783221A1 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 05/09/2007 | EP1783216A1 Telomerase-inhibitory ena oligonucleotide |
| 05/09/2007 | EP1783139A2 Human telomerase catalytic subunit |
| 05/09/2007 | EP1783136A1 Lipase inhibitor |
| 05/09/2007 | EP1783129A1 Spiropiperidyl rifamycins for the treatment of microbacterial infections |
| 05/09/2007 | EP1783128A1 Heterocyclic compounds and their use as antifouling agents |
| 05/09/2007 | EP1783127A1 Novel compound having lipase inhibitory activity |
| 05/09/2007 | EP1783126A2 N-oxides of N-phenyl-2-pyrimidine-amine derivatives |
| 05/09/2007 | EP1783124A1 2-phenylthiophene derivative |
| 05/09/2007 | EP1783123A1 Synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins |
| 05/09/2007 | EP1783120A1 Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
| 05/09/2007 | EP1783115A1 Arylamine ketones, their preparation methods, the pharmaceutical compositions containing them and their use |
| 05/09/2007 | EP1783113A2 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| 05/09/2007 | EP1782859A2 Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines |
| 05/09/2007 | EP1782839A1 Sterilization process of Glucocorticosteroid by supercritical CO2 |
| 05/09/2007 | EP1782838A1 Inhibition of infiltration, and cell killing agent |
| 05/09/2007 | EP1782834A2 Oxycodone conjugates with lower abuse potential and extended duration of action |
| 05/09/2007 | EP1782833A2 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
| 05/09/2007 | EP1782832A1 Remedy for diabetes |
| 05/09/2007 | EP1782831A1 External preparation |
| 05/09/2007 | EP1782830A1 Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist |
| 05/09/2007 | EP1782829A1 Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| 05/09/2007 | EP1782828A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 05/09/2007 | EP1782826A1 PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 05/09/2007 | EP1782818A1 Pharmaceutical composition comprising lactobacilli and symethicone for the treatment of gastrointestinal pathologies |
| 05/09/2007 | EP1782816A1 Water-based medicinal composition containing azithromycin and method of preparing the same |
| 05/09/2007 | EP1782815A1 Compounds for the treatment of an acute injury to the central nervous system |
| 05/09/2007 | EP1782814A1 Prevention of ovarian cancer by administration of a vitamin D compound |
| 05/09/2007 | EP1782813A1 The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist |
| 05/09/2007 | EP1782812A1 Compounds for the treatment of inflammation of the central nervous system |
| 05/09/2007 | EP1782811A1 Novel antimalaria agent containing heterocyclic compound |
| 05/09/2007 | EP1782810A2 Selective estrogen receptor modulators containing a phenylsulfonyl group |
| 05/09/2007 | EP1782809A1 Use of ligands of PPARGamma for inducing foetal lung maturity and the prevention of the respiratory-distress syndrome in premature infants |
| 05/09/2007 | EP1782808A1 Preventive or therapeutic agent for chronic inflammatory lung disease |
| 05/09/2007 | EP1782807A1 Jelly composition |
| 05/09/2007 | EP1782806A1 Compositions for treating dermatological and neurological disorders |
| 05/09/2007 | EP1782805A1 Composition for accelerating calcium absorption |
| 05/09/2007 | EP1782804A1 Medicinal composition as immunosuppressant |
| 05/09/2007 | EP1782803A1 Coenzyme q10-containing composition |
| 05/09/2007 | EP1782802A1 Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments |
| 05/09/2007 | EP1782801A1 Eyewash liquid for dry eye therapy |
| 05/09/2007 | EP1782800A2 JAK/STAT pathway inhibitors and the uses thereof |
| 05/09/2007 | EP1782799A2 Transdermal therapeutic system comprising an active analogue of fentanyl |
| 05/09/2007 | EP1782798A2 Ascending-dose dosage form |
| 05/09/2007 | EP1782065A2 Treatment of posterior capsule opacification |
| 05/09/2007 | EP1781714A1 Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
| 05/09/2007 | EP1781708A1 Materials and methods for immune system stimulation |
| 05/09/2007 | EP1781679A1 Antibacterial agents |
| 05/09/2007 | EP1781674A1 Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| 05/09/2007 | EP1781673A1 Selected fused heterocyclics and uses thereof |
| 05/09/2007 | EP1781671A1 Rapamycin polymorph ii and uses thereof |
| 05/09/2007 | EP1781670A1 Rifamycin derivatives for treating microbial infections |
| 05/09/2007 | EP1781669A2 Antibacterial agents |
| 05/09/2007 | EP1781668A2 Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
| 05/09/2007 | EP1781667A1 Benzothienopyridines for use as inhibitors of eg5 kinesin |
| 05/09/2007 | EP1781666A1 Improved process for making form i of olanzapine. |
| 05/09/2007 | EP1781665A2 Olanzapine salts and their conversion to olanzapine free base |
| 05/09/2007 | EP1781664A1 Inhibitors of vegf receptor and hgf receptor signaling |
| 05/09/2007 | EP1781663A2 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 05/09/2007 | EP1781662A1 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| 05/09/2007 | EP1781661A2 Vasopressin v1a antagonists |
| 05/09/2007 | EP1781660A1 Imidazopyrazine as tyrosine kinase inhibitors |
| 05/09/2007 | EP1781659A2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 05/09/2007 | EP1781658A1 Imidazoý4,5-d¨pyrimidines, their uses and methods of preparation |
| 05/09/2007 | EP1781657A2 Medicaments with hm74a receptor activity |
| 05/09/2007 | EP1781656A2 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 05/09/2007 | EP1781655A2 Triazolopyridine compounds useful for the treatment of inflammation |
| 05/09/2007 | EP1781654A1 Pyrrolo-pyridine kinase modulators |
| 05/09/2007 | EP1781653A1 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |